Patents by Inventor John H. van Duzer

John H. van Duzer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HDAC1,2 inhibitors
    Patent number: 11858919
    Abstract: Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat diseases or disorders associated with HDAC1 and/or HDAC2 activity.
    Type: Grant
    Filed: September 25, 2019
    Date of Patent: January 2, 2024
    Assignee: Regenacy Pharmaceuticals, Inc.
    Inventors: John H. Van Duzer, Ralph Mazitschek, Charles Blum
  • PIPERIDINE DERIVATIVES AS HDAC1/2 INHIBITORS
    Publication number: 20230348389
    Abstract: Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat diseases or disorders associated with HDAC1 and/or HDAC2 activity.
    Type: Application
    Filed: May 5, 2023
    Publication date: November 2, 2023
    Inventors: John H. van Duzer, Ralph Mazitschek
  • Piperidine derivatives as HDAC1/2 inhibitors
    Patent number: 11702389
    Abstract: Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat diseases or disorders associated with HDAC1 and/or HDAC2 activity.
    Type: Grant
    Filed: February 24, 2021
    Date of Patent: July 18, 2023
    Assignee: REGENACY PHARMACEUTICALS, LLC
    Inventors: John H. van Duzer, Ralph Mazitschek
  • Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof
    Patent number: 11617750
    Abstract: The present invention relates to novel “reverse amide” compounds comprising a zinc chelator group, and the use of such compounds in the inhibition of HDAC6 and in the treatment of various diseases, disorders or conditions related to HDAC6.
    Type: Grant
    Filed: August 26, 2019
    Date of Patent: April 4, 2023
    Assignee: Acetylon Pharmaceuticals, Inc.
    Inventors: John H. van Duzer, Ralph Mazitschek, Walter Ogier, James E. Bradner, Guoxiang Huang, Dejian Xie, Nan Yu
  • Substituted piperazines as selective HDAC1,2 inhibitors
    Patent number: 11542242
    Abstract: Provided herein are compounds of Formula IV, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat diseases or disorders associated with HDAC1 and/or HDAC2 activity.
    Type: Grant
    Filed: August 19, 2020
    Date of Patent: January 3, 2023
    Assignee: REGENACY PHARMACEUTICALS, LLC
    Inventors: John H. van Duzer, Ralph Mazitschek
  • SUBSTITUTED PIPERAZINES AS SELECTIVE HDAC1,2 INHIBITORS
    Publication number: 20220281833
    Abstract: Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat diseases or disorders associated with HDAC1 and/or HDAC2 activity.
    Type: Application
    Filed: May 17, 2022
    Publication date: September 8, 2022
    Inventors: John H. van Duzer, Ralph Mazitschek
  • HDAC1,2 Inhibitors
    Publication number: 20220033388
    Abstract: Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat diseases or disorders associated with HDAC1 and/or HDAC2 activity.
    Type: Application
    Filed: September 25, 2019
    Publication date: February 3, 2022
    Inventors: John H. VAN DUZER, Ralph MAZITSCHEK, Charles BLUM
  • PYRIMIDINE AND PYRAZINE HDAC1,2 INHIBITORS
    Publication number: 20210332036
    Abstract: Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat diseases or disorders associated with HDAC1 and/or HDAC2 activity.
    Type: Application
    Filed: October 9, 2019
    Publication date: October 28, 2021
    Inventors: John H. VAN DUZER, Ralph MAZITSCHEK, Charles BLUM, Matthew B. JARPE
  • PIPERIDINE DERIVATIVES AS HDAC1/2 INHIBITORS
    Publication number: 20210179559
    Abstract: Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat diseases or disorders associated with HDAC1 and/or HDAC2 activity.
    Type: Application
    Filed: February 24, 2021
    Publication date: June 17, 2021
    Inventors: John H. van Duzer, Ralph Mazitschek
  • Piperidine derivatives as HDAC1/2 inhibitors
    Patent number: 10968180
    Abstract: Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat diseases or disorders associated with HDAC1 and/or HDAC2 activity.
    Type: Grant
    Filed: June 6, 2019
    Date of Patent: April 6, 2021
    Assignee: Regenacy Pharmaceuticals, LLC
    Inventors: John H. van Duzer, Ralph Mazitschek
  • Phenyl and pyridinyl hydroxamic acids
    Patent number: 10927072
    Abstract: The present invention relates to pyrimidine hydroxy amide compounds, the use of such compounds in the inhibition of HDAC6, and the use of such compounds in the treatment of various diseases, disorders, or conditions related to HDAC6.
    Type: Grant
    Filed: July 19, 2019
    Date of Patent: February 23, 2021
    Assignee: ACETYLON PHARMACEUTICALS, INC.
    Inventors: John H. van Duzer, Ralph Mazitschek
  • SUBSTITUTED PIPERAZINES AS SELECTIVE HDAC1,2 INHIBITORS
    Publication number: 20200377465
    Abstract: Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat diseases or disorders associated with HDAC1 and/or HDAC2 activity.
    Type: Application
    Filed: August 19, 2020
    Publication date: December 3, 2020
    Inventors: John H. van Duzer, Ralph Mazitschek
  • Substituted piperazines as selective HDAC1,2 inhibitors
    Patent number: 10774056
    Abstract: Provided herein are substituted piperazine compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat diseases or disorders associated with HDAC1 and/or HDAC2 activity.
    Type: Grant
    Filed: July 10, 2019
    Date of Patent: September 15, 2020
    Assignee: REGENACY PHARMACEUTICALS, INC.
    Inventors: John H. van Duzer, Ralph Mazitschek
  • Reverse Amide Compounds As Protein Deacetylase Inhibitors And Methods Of Use Thereof
    Publication number: 20200030325
    Abstract: The present invention relates to novel “reverse amide” compounds comprising a zinc chelator group, and the use of such compounds in the inhibition of HDAC6 and in the treatment of various diseases, disorders or conditions related to HDAC6.
    Type: Application
    Filed: August 26, 2019
    Publication date: January 30, 2020
    Inventors: John H. van Duzer, Ralph Mazitschek, Walter Olgier, James E. Bradner, Guoxiang Huang, Dejian Xie, Nan Yu
  • PHENYL AND PYRIDINYL HYDROXAMIC ACIDS
    Publication number: 20200010407
    Abstract: The present invention relates to pyrimidine hydroxy amide compounds, the use of such compounds in the inhibition of HDAC6, and the use of such compounds in the treatment of various diseases, disorders, or conditions related to HDAC6.
    Type: Application
    Filed: July 19, 2019
    Publication date: January 9, 2020
    Inventors: John H. van Duzer, Ralph Mazitschek
  • PIPERIDINE DERIVATIVES AS HDAC1/2 INHIBITORS
    Publication number: 20190359569
    Abstract: Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat diseases or disorders associated with HDAC1 and/or HDAC2 activity.
    Type: Application
    Filed: June 6, 2019
    Publication date: November 28, 2019
    Inventors: John H. van Duzer, Ralph Mazitschek
  • Crystalline forms of a histone deacetylase inhibitor
    Patent number: 10464906
    Abstract: This disclosure provides solid forms of 2-((2-chlorophenyl)(phenyl)amino)-N-(7-(hydroxyamino)-7-oxoheptyl)pyrimidine-5-carboxamide, and methods of manufacturing and using these forms.
    Type: Grant
    Filed: June 8, 2016
    Date of Patent: November 5, 2019
    Assignee: ACETYLON PHARMACEUTICALS, INC.
    Inventors: John H. van Duzer, Farzaneh Seyedi, Gui Liu
  • SELECTIVE HDAC1,2 INHIBITORS
    Publication number: 20190330169
    Abstract: Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat diseases or disorders associated with HDAC1 and/or HDAC2 activity.
    Type: Application
    Filed: July 10, 2019
    Publication date: October 31, 2019
    Inventors: John H. van Duzer, Ralph Mazitschek
  • Substituted piperazines as selective HDAC1,2 inhibitors
    Patent number: 10385031
    Abstract: Provided herein are compounds of Formula II, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat diseases or disorders associated with HDAC1 and/or HDAC2 activity
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: August 20, 2019
    Assignee: REGENACY PHARMACEUTICALS, LLC
    Inventors: John H. van Duzer, Ralph Mazitschek
  • Phenyl and pyridinyl hydroxamic acids
    Patent number: 10370324
    Abstract: The present invention relates to pyrimidine hydroxy amide compounds, the use of such compounds in the inhibition of HDAC6, and the use of such compounds in the treatment of various diseases, disorders, or conditions related to HDAC6.
    Type: Grant
    Filed: November 9, 2017
    Date of Patent: August 6, 2019
    Assignee: Acetylon Pharmaceuticals, Inc.
    Inventors: John H. van Duzer, Ralph Mazitschek